Let's Wait A Little More Before Buying Palantir

Summary
- Palantir has immense opportunity as the world seeks to harness the power of the data.
- The company has great software that delivers a sticky product, high margin, and a near-ubiquitous application to its service.
- However, due to the absurd stock-based compensation and a high valuation, I believe it is better to wait a little more before buying Palantir.
Michael Vi/iStock Editorial via Getty Images
Introduction and Thesis
Our future is inevitably data. Since the age of the internet, digitalization in all aspects of our society has been ongoing creating massive amounts of data. In the future, the one that can harness this data will be miles ahead of their competitors, so the ability to process this massive data is expected to be extremely valuable.
Palantir (NYSE:PLTR) is a company building "software that empowers organizations to effectively integrate their data, decisions, and operations," or in other words, Plantar is the company that is at the forefront of harnessing the power of data to solve enterprise-level extremely complex problems. Thus, being a leader in this industry makes the company's fundamentals and vision extremely attractive; however, I believe it is better for investors to wait for the time being before investing in Palantir. The economic policies and the market sentiments are moving away from the expansionary policy potentially opening up the possibility for further consolidation in Palantir stocks. Further, the massive amounts of stock-based compensation (SBC) that the company is justifying are unfriendly to shareholders. I think it is better for either the company to reduce SBC or wait until the revenue growth makes SBC a smaller part of the overall revenue.
Fundamentals
Before talking about the absurd valuation and the SBC, I would like to point out the marvelous business that Palantir has briefly pointed out that the only problem that the company or the stock has is its SBC and valuation.
Palantir's business is beautiful; it can be applied to governments and commercial customers in any industry. The company has the National Institute of Health, Department of Veteran Affairs, Army, Air Force, and etc., as its government customers who utilize Palantir's software to tackle everything from defense and intelligence gathering to improving veteran patient cares. Further, Palantir's commercial software applications are as flexible as the government business. The company has numerous enterprises as its customers including L3Harris (LHX), Airbus (OTCPK:EADSF), Ferrari (RACE), Rio Tinto (RIO), and etc. improving everything from manufacturing to mining. This alone shows investors the power of harnessing the data and the opportunity Palantir has moving forward into the future.
As a result of such a promising and dynamic product, the company's operational growth and financial health have been firing on all cylinders. In 2021Q3, Palantir reported revenue of $392 million, which was 36% growth year-over-year while the customer count grew even faster at 46%. I believe customer growth promises future revenue growth because it takes months to years for revenue to meaningfully materialize, so the fact that the customer growth grew even faster than the revenue growth was significant. Further, adjusted free cash flow turned positive to $119 million compared to -$53 million 2020Q3. The adjusted operating margins continued to be at 30% while the adjusted gross margin was at an impressive 82%. The company, in simple words, is showing growth and improving operations.
Stock-Based Compensation
Despite the promising fundamental thesis and top-line growth that the company has been showing, I do not believe Palantir stock is a buy at the moment because of massive SBC. The company has been massively diluting its shareholder base through absurd SBC citing that they need to attract talent, which may be true to some extent. As the chart below shows, since the IPO on September 30th, 2020, the company's outstanding shares increased from about 900 million to 1.964 billion, which is over 100% dilution. When calculating the dilution from the start of 2021 at 1.8 billion shares, the company has diluted shareholders by 10% in 2021 alone. I think this is simply absurd and shows the unfriendly attitude of the management towards its shareholder.
[Chart created by author using YCharts from Seeking Alpha]
To better understand how serious the dilution or the SBC is, I created a chart below showing the stock-based compensation data throughout 2021. As you can see in the chart below, SBC consistently represented over 50% of the company's revenue. It is the biggest cost for the company, and it has been the reason why the company has been reporting a net loss.
2021 Q1~Q3 (In Millions) | |||
Q1 | Q2 | Q3 | |
Revenue | $341 | $376 | $392 |
SBC | $194 | $233 | $185 |
Cost Incurred Because of SBC | $37 | $30 | $23 |
Total SBC Cost | $231 | $263 | $208 |
SBC/Revenue | 67.74% | 69.95% | 53.06% |
[Chart created by author using Source 1, Source 2, and Source 3]
SBC is a great way to reward employees and attract talent in the market. However, Palantir, in my opinion, has been degrading shareholder value due to excessive SBC. Thus, until either the SBC shows a decreasing trend or the SBC becomes irrelevantly small in comparison to the revenue, I believe investors should think twice before investing in Palantir.
Financials and Valuation
Unlike valuations, I believe the financial health of Palantir's balance sheet is great. The company currently has about $2.3 billion in cash with about $3.2 billion in total assets while the total liability stood at only $987 million putting total liability to asset ratio (L/A) at 43%. Further, because the company generated about $240 million during operation with negligible long-term debt, I believe the financial situation of Palantir is great.
On the other hand, Palantir's valuation is slightly questionable. The company has a market capitalization of about $37 billion dollars today. The company has a high price to sales ratio of about 28 with an expected forward price to earnings ratio of about 120. It is true that the company's business is high margin and crucial, but considering the SBC and today's economic conditions, I believe this valuation may be too high. Unlike in most of 2020 and 2021, the Federal Reserve is ending the expansionary policy. Instead, they are expecting to finish tapering by March of 2022 and raise rates possible in March, which will effectively raise long-term treasury rates and decrease the investment in the stock market. Therefore, a higher valuation might have been justified in the previous 2 years, but going into 2022, I believe a higher valuation may result in either contraction or range-bound trading for the time being.
Summary
Palantir is a unique company and a perfect example of a great company but a bad stock. I truly believe in the power and the potential of Palantir's software. It can be applied in almost any industry from healthcare to defense to manufacturing. However, the company's excessive stock-based compensation and valuation hesitate me. The company has been justifying its high stock-based compensation without showing signs of stopping, and I believe this is just taking advantage of its shareholders by diluting their value. Therefore, I believe it is better to wait until stock-based compensation is either showing a decreasing trend or becoming a smaller portion of the revenue due to Palantir's continued growth.
This article was written by
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Recommended For You
Comments (86)

Yeah, they did buy up some boomie rocks.





That’s the thing with fat bonuses, hard to discontinue them without royally pissing off the team.Words of wisdom. Never instill an reward program if you can't maintain it. The pain of loss hurts more than the pain of no gain.


None of you are Nostradamus, so the bottom is unknown. Throwing out numbers helps nobody. Maybe the stock hits 8. Maybe you came up with that throwing darts.
Adding small amounts at 16-18 does not seem illogical. Adding larger amounts at lower prices makes sense. If you are in for the long term at a cost average of 17 versus 14, that is not huge. Of course, you would like to buy as low as possible. Problem is nobody knows what the low will be.
Soon it will attain 'Monopoly Money' status. I'm out.








